Organon & Co. (NYSE:OGN) Reaches New 1-Year High – Should You Buy?

Organon & Co. (NYSE:OGN)’s stock price reached a new 52-week high on Thursday . The company traded as high as $13.70 and last traded at $13.66, with a volume of 5548898 shares changing hands. The stock had previously closed at $13.65.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on OGN. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane reiterated a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Performance

The firm has a market capitalization of $3.59 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 1.26 and a beta of 1.55. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. The company’s fifty day moving average price is $13.51 and its two-hundred day moving average price is $10.68.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio is 10.39%.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers increased its position in Organon & Co. by 1.7% during the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company’s stock worth $288,000 after purchasing an additional 788 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Organon & Co. by 0.6% in the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after buying an additional 1,570 shares during the period. Integrated Wealth Concepts LLC lifted its position in Organon & Co. by 2.8% during the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after buying an additional 1,594 shares in the last quarter. Rafferty Asset Management LLC lifted its position in Organon & Co. by 8.5% during the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock valued at $228,000 after buying an additional 1,847 shares in the last quarter. Finally, Bank of Nova Scotia grew its stake in Organon & Co. by 4.6% during the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company’s stock worth $475,000 after buying an additional 1,947 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.